Literature DB >> 30885858

Percutaneous Endoscopic C2-C3 Medial Branches Neurotomy for Cervicogenic Headache.

Ni Bing1, Du Tao1, Shu Wei1, Lu Guang1, Zhu Hongwei2.   

Abstract

BACKGROUND: Cervicogenic headache (CEH) is characterized by unilateral posterior head and neck pain originating from cervical structures and may be improved or resolved by successful treatment of the causative cervical disorder or lesion. Cervical medial branch radiofrequency (RF) lesion therapy is effective in some CEH patients with no significant pathologic abnormalities that can be surgically corrected. However, patients with refractory CEH are often encountered clinically. CASE DESCRIPTION: Here we describe the case of a 68-year-old female with an 18-year history of CEH who did not respond to a series of treatments including nonsteroidal antiinflammatory drugs, anticonvulsants, medial branch diagnostic block, medial branch RF lesion, and spinal cord stimulation. After careful examination, we performed percutaneous endoscopic right C2-C3 medial branch neurotomy under local anesthesia and neuroleptanalgesia. The patient's constant pain was ultimately relieved.
CONCLUSIONS: For patients with refractory CEH who failed medial branch RF lesion, which could be relieved briefly by diagnostic medial branch injection, percutaneous endoscopic C2-C3 medial branches neurotomy may alleviate their pain under the premise of full informed consent, accurate localization, careful intraoperative exploration, and stimulation testing.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical medial branch; Cervicogenic headache; Endoscopic; Neurotomy; Radiofrequency

Year:  2019        PMID: 30885858     DOI: 10.1016/j.wneu.2019.03.072

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  1 in total

1.  Acupuncture plus massage for cervicogenic headache: A protocol for systematic review and meta-analysis.

Authors:  Fangfang Ding; Zhen Liu; Rui Li; Chenying Wang; Yan Lu
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.